Pharmacometrics: A multidisciplinary field to facilitate critical thinking in drug development and translational research settings

Journal of Clinical Pharmacology

Volumn 48, Issue 5, 2008, Pages 632-649

  Barrett, Jeffrey S ^a,b,f   Fossler, Michael J ^c   Cadieu, K David ^d   Gastonguay, Marc R ^e  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d KDC Group Inc   (United States)

^e Metrum Institute   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clinical pharmacology; Critical path; Education; NIH roadmap; Pharmacometrics

Indexed keywords

CRITICAL THINKING; DECISION MAKING; DRUG INDUSTRY; DRUG RESEARCH; FIELD STUDY; HUMAN; MEDICAL EDUCATION; QUANTITATIVE ANALYSIS; REVIEW;

CURRICULUM; DRUG DESIGN; EDUCATION, PROFESSIONAL; FACULTY; HUMANS; INTERDISCIPLINARY COMMUNICATION; PHARMACOKINETICS; RESEARCH; STUDENTS, HEALTH OCCUPATIONS; TECHNOLOGY TRANSFER;

EID: 41849150709     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008315318     Document Type: Review

References (44)

1. Lee WH, Fujiwara M. Pharmacometrics of guinea pig's gall-bladder in vitro [in Chinese]. Taiwan Yi Xue Hui Za Zhi. 1971 ; 70: 687-696.
2. Lee C., Barnes A., Katz RL Neuromuscular sensitivity to tubocurarine. A comparison of 10 parameters. Br J Anaesth. 1976 ; 48: 1045-1051.
3. Williams PJ, Ette EI Pharmacometrics: impacting drug development and pharmacotherapy. In: Pharmacometrics: The Science of Quantitative Pharmacology. EI Ette, PJ Williams, eds. Hoboken, NJ: John Wiley & Sons ; 2007: 1-21.
4. Barrett JS Applying quantitative pharmacology in an academic translational research environment. AAPS J. In press.
5. Zerhouni E., Medicine. The NIH roadmap. Science. 2003 ; 302: 63-72.
6. Center for Drug Evaluation and Research (CDER). Innovation and stagnation: challenge and opportunity on the critical path to new medicinal products. US Food and Drug Administration. 2004.
7. Gieschke R., Reigner BG, Steimer JL Exploring clinical study design by computer simulation based on pharmacokinetic/ pharmacodynamic modelling. Int J Clin Pharmacol Ther. 1997 ; 35: 469-474.
8. Gieschke R., Burger HU, Reigner B., et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol. 2003 ; 55: 252-263.
9. Bruno R., Vivier N., Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996 ; 24: 153-172.
10. Veyrat-Follet C., Bruno R., Olivares R., et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther. 2000 ; 68: 677-687.
11. Zhang L., Sinha V., Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn. 2006 ; 33: 369-393.
12. Sarkar S., Mitlak BH, Wong M., et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002 ; 17: 1-10.
13. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: 4-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 ; 87: 3609-3617.
14. Noble D., Levin J., Scott W. Biological simulations in drug discovery. Drug Discov Today. 1999 ; 4: 10-16.
15. Lesko LJ, Rowland M., Peck CC, et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000 ; 17: 1335-1344.
16. Drusano GL, Louie A., Deziel M., et al. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis. 2006 ; 42: 525-532.
17. Hutmacher MM, Mukherjee D., Kowalski KG, et al. Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist. J Pharmacokinet Pharmacodyn. 2005 ; 32: 501-520.
18. Gieschke R., Steimer JL Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet. 2000 ; 25: 49-58.
19. Bortz DM, Nelson PW Model selection and mixed-effects modeling of HIV infection dynamics. Bull Math Biol. 2006 ; 68: 2005-2025.
20. Lindsay R., Pack S., Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int. 2005 ; 16: 306-312.
21. Mostafavi S., Baranzini S., Oksernberg J., et al. Predictive modeling of therapy response in multiple sclerosis using gene expression data. Conf Proc IEEE Eng Med Biol Soc. 2006 ; 1: 5519-5522.
22. van der Helm-van Mil AH, le Cessie, S., van Dongen H., et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007 ; 56: 433-440.
23. Anderson JJ, Bolognese JA, Felson DT Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum. 2003 ; 48: 3031-3038.
24. Barton P., Jobanputra P., Wilson J., et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumor necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004 ; 8: iii, 1-91.
25. Barnett J. Directors of pharmacology graduate programs: Pharm Phorum. Mol Interv. 2006 ; 6: 4-7.
26. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007 ; 82: 21-32.
27. Grasela TH, Fiedler-Kelly J., Walawander CA, et al. Challenges in the transition to model-based development. AAPS J. 2005 ; 7: E488 - E495.
28. Grasela TH, Dement CW, Kolterman OG, et al. Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther. 2007 ; 82: 137-142.
29. Atkinson AJ Jr, Lalonde RL Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther. 2007 ; 82: 3-6.
30. Powell JR, Gobburu JV Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther. 2007 ; 82: 97-102.
31. Gobburu JV, Marroum PJ Utilization of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision making. Clin Pharmacokinet. 2001 ; 40: 883-892.
32. Zerhouni EA Translational and clinical science-time for a new vision. N Engl J Med. 2005 ; 353: 1621-1623.
33. Zerhouni EA, Alving B. Clinical and translational science awards: a framework for a national research agenda. Transl Res. 2006 ; 148: 4-5.
34. Barrett JS Facilitating compound progression of antiretroviral agents via modeling and simulation. J Neuroimmune Pharmacol. 2007 ; 2: 58-71.
35. Bonate P. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York, NY: Springer ; 2006.
36. Holford N., Karlsson MO Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin Pharmacol Ther. 2007 ; 82: 103-105.
37. Lertora JJ, Atkinson AJ Jr. Clinical pharmacology education and training at the National Institutes of Health. Clin Pharmacol Ther. 2007 ; 81: 907-909.
38. Collier AC The role of pharmacology in medical teaching. Hawaii Med J. 2007 ; 66: 135-136.
39. Mehvar R. Development and application of an online module for teaching Bayesian forecasting principles in a clinical pharmacokinetics course. Am J Pharm Educ. 2000 ; 64: 121-125.
40. Maxwell SR, McQueen DS, Ellaway R. eDrug: a dynamic interactive electronic drug formulary for medical students. Br J Clin Pharmacol. 2006 ; 62: 673-681.
41. Hughes DA, Walley T. Economic evaluations during early (phase II) drug development: a role for clinical trial simulations ? Pharmacoeconomics. 2001 ; 19: 1069-1077.
42. Sheiner LB Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997 ; 61: 275-291.
43. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 2005 ; 7: E503 - E512.
44. Bhattaram VA, Bonapace C., Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther. 2007 ; 81: 213-221.